Thai VC Disrupt Health Impact Fund Makes First Investment in Germany’s DiaMonTech

Disrupt Health Impact Fund, a venture capital fund based in Thailand, has announced its inaugural investment in DiaMonTech, a German deeptech startup specializing in non-invasive glucose monitoring technology. This investment launched its healthcare-focused fund in May 2024 to support innovation within the sector.

DiaMonTech holds several patents for its technology, enabling accurate glucose measurements without blood collection. The Disrupt Health Impact Fund’s investment in DiaMonTech will provide the startup with valuable connections to healthcare experts across Southeast Asia’s public and private sectors. 

This support will aid DiaMonTech in establishing a foothold in the region, accelerating its ability to reach a wider audience and making its non-invasive glucose monitoring technology more accessible, particularly to those in need. The device, which measures blood glucose levels without painful finger pricking, offers an advantage over traditional methods, enabling users to manage their diabetes more conveniently and frequently.

Thorsten Lubinski, Co-Founder and CEO of DiaMonTech, expressed that this partnership will play a crucial role in the company’s expansion into Southeast Asia. He highlighted the opportunity to connect with meaningful opportunities that will positively impact people living with diabetes and those monitoring their blood sugar for preventive health care. The company’s non-invasive glucose meter, currently awaiting FDA approval, offers a user-friendly and accurate solution, providing glucose readings in 30 seconds through a spectroscopic method.

The investment aligns with the global healthcare trends identified by Disrupt Health Impact Fund’s Chairman, Krating Poonpol, who emphasized healthcare’s role in driving the growth of the global economy. 

With the increasing aging population, rising life expectancies worldwide, and the growing demand for self-care products, the healthcare sector is expected to grow substantially. The self-care medical device market alone is predicted to increase from $24.4 billion in 2023 to $42.6 billion by 2032. 

Naranpat Thitipattakul, Partner at the Disrupt Health Impact Fund, elaborated on the rigorous selection process that led to the investment in DiaMonTech. Out of over 1,000 startups globally, DiaMonTech stood out due to its sophisticated and difficult-to-replicate technology developed over a decade of research at Goethe University. 

The device’s proven accuracy and scientific backing were key factors in the fund’s investment decision. This technology presents a market opportunity and promises to improve public healthcare outcomes, particularly for diabetic patients, by making diabetes management more accessible and less intrusive.

The fund is focused on five core areas: Self-Care, Preventive Care, Silver Age, Holistic Wellness, and Smart Hospitals. It seeks to invest in companies that have either commercialized their innovations or are in clinical trials, with a particular emphasis on those seeking FDA approval. 

The number of investors backing the fund has expanded to seven, with three new individual investors joining. These investors share a keen interest in the Health and wellness sector and are eager to support promising companies while expanding business opportunities. The fund remains open to additional partners looking to co-invest and continues to search for potential Healthcare Deep Tech companies to enhance its portfolio.